These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 33238481)

  • 1. Pre-Existing Cardiovascular Conditions as Clinical Predictors of Myocarditis Reporting with Immune Checkpoint Inhibitors: A VigiBase Study.
    Noseda R; Ruinelli L; Gaag LCV; Ceschi A
    Cancers (Basel); 2020 Nov; 12(11):. PubMed ID: 33238481
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Haemophagocytic lymphohistiocytosis in patients treated with immune checkpoint inhibitors: analysis of WHO global database of individual case safety reports.
    Noseda R; Bertoli R; Müller L; Ceschi A
    J Immunother Cancer; 2019 May; 7(1):117. PubMed ID: 31046841
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Coronary and aortic calcification are associated with cardiovascular events on immune checkpoint inhibitor therapy.
    Schiffer WB; Deych E; Lenihan DJ; Zhang KW
    Int J Cardiol; 2021 Jan; 322():177-182. PubMed ID: 32800916
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune checkpoint inhibitor monotherapy is associated with less cardiac toxicity than combination therapy.
    Cone EB; Haeuser L; Reese SW; Marchese M; Nguyen DD; Nabi J; Chou WH; Noldus J; McKay RR; Kilbridge KL; Trinh QD
    PLoS One; 2022; 17(11):e0272022. PubMed ID: 36318537
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immune Checkpoint Inhibitor-Related Cytokine Release Syndrome: Analysis of WHO Global Pharmacovigilance Database.
    Ceschi A; Noseda R; Palin K; Verhamme K
    Front Pharmacol; 2020; 11():557. PubMed ID: 32425791
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Late cardiac adverse events in patients with cancer treated with immune checkpoint inhibitors.
    Dolladille C; Ederhy S; Allouche S; Dupas Q; Gervais R; Madelaine J; Sassier M; Plane AF; Comoz F; Cohen AA; Thuny FR; Cautela J; Alexandre J
    J Immunother Cancer; 2020 Jan; 8(1):. PubMed ID: 31988143
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Thymus alterations and susceptibility to immune checkpoint inhibitor myocarditis.
    Fenioux C; Abbar B; Boussouar S; Bretagne M; Power JR; Moslehi JJ; Gougis P; Amelin D; Dechartres A; Lehmann LH; Courand PY; Cautela J; Alexandre J; Procureur A; Rozes A; Leonard-Louis S; Qin J; ; Cheynier R; Charmeteau-De Muylder B; Redheuil A; Tubach F; Cadranel J; Milon A; Ederhy S; Similowski T; Johnson DB; Pizzo I; Catalan T; Benveniste O; Hayek SS; Allenbach Y; Rosenzwajg M; Dolladille C; Salem JE
    Nat Med; 2023 Dec; 29(12):3100-3110. PubMed ID: 37884625
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Myocarditis in Patients Treated With Immune Checkpoint Inhibitors.
    Mahmood SS; Fradley MG; Cohen JV; Nohria A; Reynolds KL; Heinzerling LM; Sullivan RJ; Damrongwatanasuk R; Chen CL; Gupta D; Kirchberger MC; Awadalla M; Hassan MZO; Moslehi JJ; Shah SP; Ganatra S; Thavendiranathan P; Lawrence DP; Groarke JD; Neilan TG
    J Am Coll Cardiol; 2018 Apr; 71(16):1755-1764. PubMed ID: 29567210
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between immune checkpoint inhibitor-induced myocarditis and concomitant use of thiazide diuretics.
    Mitsuboshi S; Hamano H; Niimura T; Ozaki AF; Patel PM; Lin TJ; Tanaka Y; Kimura I; Iwata N; Shiromizu S; Chuma M; Koyama T; Yamanishi Y; Kanda Y; Ishizawa K; Zamami Y
    Int J Cancer; 2023 Oct; 153(8):1472-1476. PubMed ID: 37306521
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Burden of Cardiovascular Disease in Immune Checkpoint Inhibitor-Treated Patients: Reconciling Adjudicated and Coded Outcomes.
    Kondapalli L; Hsia J; Miller R; Flaig TW; Bonaca MP
    JACC CardioOncol; 2022 Dec; 4(5):649-656. PubMed ID: 36636437
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Immune Checkpoint Inhibitor-Associated Myocarditis.
    Ganatra S; Neilan TG
    Oncologist; 2018 Aug; 23(8):879-886. PubMed ID: 29802219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influenza vaccination and myocarditis among patients receiving immune checkpoint inhibitors.
    Awadalla M; Golden DLA; Mahmood SS; Alvi RM; Mercaldo ND; Hassan MZO; Banerji D; Rokicki A; Mulligan C; Murphy SPT; Jones-O'Connor M; Cohen JV; Heinzerling LM; Armanious M; Sullivan RJ; Damrongwatanasuk R; Chen CL; Gupta D; Kirchberger MC; Moslehi JJ; Shah SP; Ganatra S; Thavendiranathan P; Rizvi MA; Sahni G; Lyon AR; Tocchetti CG; Mercurio V; Thuny F; Ederhy S; Mahmoudi M; Lawrence DP; Groarke JD; Nohria A; Fradley MG; Reynolds KL; Neilan TG
    J Immunother Cancer; 2019 Feb; 7(1):53. PubMed ID: 30795818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intensified immunosuppressive therapy in patients with immune checkpoint inhibitor-induced myocarditis.
    Cautela J; Zeriouh S; Gaubert M; Bonello L; Laine M; Peyrol M; Paganelli F; Lalevee N; Barlesi F; Thuny F
    J Immunother Cancer; 2020 Dec; 8(2):. PubMed ID: 33298621
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Emerging role of immune checkpoint inhibitors and their relevance for the cardiovascular system.
    Michel L; Totzeck M; Lehmann L; Finke D
    Herz; 2020 Nov; 45(7):645-651. PubMed ID: 32533218
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association of early electrical changes with cardiovascular outcomes in immune checkpoint inhibitor myocarditis.
    Power JR; Alexandre J; Choudhary A; Ozbay B; Hayek SS; Asnani A; Tamura Y; Aras M; Cautela J; Thuny F; Gilstrap L; Arangalage D; Ewer S; Huang S; Deswal A; Palaskas NL; Finke D; Lehmann LH; Ederhy S; Moslehi J; Salem JE;
    Arch Cardiovasc Dis; 2022 May; 115(5):315-330. PubMed ID: 35595646
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immune checkpoint inhibitor myocarditis: elucidating the spectrum of disease through endomyocardial biopsy.
    Palaskas NL; Segura A; Lelenwa L; Siddiqui BA; Subudhi SK; Lopez-Mattei J; Durand JB; Deswal A; Zhao B; Maximilian Buja L; Iliescu C
    Eur J Heart Fail; 2021 Oct; 23(10):1725-1735. PubMed ID: 34114291
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immune checkpoint inhibitor-induced myocarditis in cancer patients: a case report and review of reported cases.
    Matzen E; Bartels LE; Løgstrup B; Horskær S; Stilling C; Donskov F
    Cardiooncology; 2021 Aug; 7(1):27. PubMed ID: 34365980
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The spectrum of cardiovascular complications related to immune-checkpoint inhibitor treatment : Including myocarditis and the new entity of non inflammatory left ventricular dysfunction.
    Andres MS; Ramalingam S; Rosen SD; Baksi J; Khattar R; Kirichenko Y; Young K; Yousaf N; Okines A; Huddart R; Harrington K; Furness AJS; Turajlic S; Pickering L; Popat S; Larkin J; Lyon AR
    Cardiooncology; 2022 Nov; 8(1):21. PubMed ID: 36424659
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical Characteristics and Outcomes in Immune Checkpoint Inhibitor Therapy-Associated Myocarditis.
    Thakker RA; Lee MA; Albaeni A; Elbadawi A; Suthar KH; Perez C; Sonstein LK; Farr NM; Venkatesan R; Khalife W; Berbarie RF; Chatila KF
    Cardiol Res; 2021 Oct; 12(5):270-278. PubMed ID: 34691324
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immune Checkpoint Inhibitor-Related Myositis Overlapping With Myocarditis: An Institutional Case Series and a Systematic Review of Literature.
    Nakagomi Y; Tajiri K; Shimada S; Li S; Inoue K; Murakata Y; Murata M; Sakai S; Sato K; Ieda M
    Front Pharmacol; 2022; 13():884776. PubMed ID: 35645839
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.